Literature DB >> 17523276

Is p53 and heat shock protein 70 expression a useful parameter for preoperative hyperthermoradiation therapy in advanced rectal carcinoma.

Kunio Takeuchi1, Masanobu Nakajima, Tatsuya Miyazaki, Munenori Ide, Takayuki Asao, Kiníchi Fujita, Hiroyuki Kuwano.   

Abstract

BACKGROUND/AIMS: The purposes of preoperative hyperthermoradiation (HR) therapy in advanced rectal carcinoma is to decrease the tumor mass and local recurrence after the operation and to improve long-term survival. The aim of this study was to investigate useful parameters of preoperative HR therapy in advanced rectal carcinoma.
METHODOLOGY: Thirty-seven patients with primary advanced rectal carcinoma located in the lower part of the rectum were treated with preoperative HR therapy followed by a curative resection of the rectum. Immunohistochemical staining for p53 and heat shock protein (HSP) 70 was performed on biopsied specimens obtained from 24 of them.
RESULTS: For both p53- and HSP 70-positive tumors the effect of HR therapy was good and survival rates were better than with for other tumors, but there was no significant correlation between HSP 70 expression and the effect of HR therapy and survival rates. And there was also no significant correlation between p53 expression and the effect of HR therapy and survival rates. HR therapy had a significant effect on the G or G4 tumors compared with G1 or G2 tumors (p = 0.0277).
CONCLUSIONS: Immunohistochemical detection of p53 and HSP 70 expressions may be useful for hyperthermoradiosensitive patients with advanced rectal carcinoma selected for preoperative HR therapy. HR therapy had a significant effect on G3 or G4 tumors compared with G1 or G2 tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17523276

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Outcomes of surgical treatment in patients with anorectal fistula cancer.

Authors:  Katsuya Osone; Hiroomi Ogawa; Chika Katayama; Yuta Shibasaki; Kunihiko Suga; Chika Komine; Naoya Ozawa; Takuhisa Okada; Takuya Shiraishi; Ryuji Katoh; Makoto Sakai; Akihiko Sano; Takehiko Yokobori; Nozomi Matsumura; Makoto Sohda; Ken Shirabe; Hiroshi Saeki
Journal:  Surg Case Rep       Date:  2021-01-26

2.  P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.

Authors:  Min-Bin Chen; Xiao-Yang Wu; Rong Yu; Chen Li; Li-Qiang Wang; Wei Shen; Pei-Hua Lu
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.